TGNA:FRA
Transgene SA
0,67 €
arrow_downward
-0,59%(-0,0040) 1D
14 tet, 8:03:02 p.d., GMT+2 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për TGNA...
Hap
0,67 €
I lartë
0,67 €
I ulët
0,67 €
Kapitalizimi i tregut
193,04 mln
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
1,48 €
Minimumi 52-javor
0,60 €
Fitimet për aksion
-0,17 €
Numri i punonjësve
152
Hap
0,67 €
I lartë
0,67 €
I ulët
0,67 €
Kapitalizimi i tregut
193,04 mln
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
1,48 €
Minimumi 52-javor
0,60 €
Fitimet për aksion
-0,17 €
Numri i punonjësve
152
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Seeking Alpha
·
1 orë më parë
Nasdaq tumbles 2%, and these 10 stocks have fueled the selloff
ChartMill
·
18 minuta më parë
Discover which dow jones stocks are making waves on Wednesday.
MarketBeat
·
24 minuta më parë
IBEX Limited (NASDAQ:IBEX) Sees Significant Drop in Short Interest
Profili
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Rreth Transgene SA